Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

334.58
-3.9900-1.18%
Post-market: 336.161.58+0.47%16:34 EDT
Volume:173.53K
Turnover:58.76M
Market Cap:9.32B
PE:-26.01
High:348.00
Open:340.00
Low:334.00
Close:338.57
52wk High:392.70
52wk Low:37.25
Shares:27.85M
Float Shares:24.08M
Volume Ratio:0.71
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:6.95
PE(LYR):-24.83

Loading ...

Praxis Precision Medicines - FDA Extends Review Period for Relutrigine Nda for Scn2a and Scn8a Dees by Three Months

THOMSON REUTERS
·
Jun 30

Praxis Precision Medicines - FDA Sets Updated Pdufa Date of December 27, 2026 for Relutrigine

THOMSON REUTERS
·
Jun 30

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

GlobeNewswire
·
Jun 30

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 29

Praxis Precision Med is Maintained at Buy by Needham

Dow Jones
·
Jun 29

Praxis Precision Medicines Inc : Needham Raises Target Price to $575 from $537

THOMSON REUTERS
·
Jun 29

U.S. Research Roundup-3m Co, Nike, Primoris Services

Reuters
·
Jun 29

Praxis Precision Medicines Director Jill Desimone Disposes of Common Shares Worth $3.23 Million

Reuters
·
Jun 27

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 23

Praxis wins FDA breakthrough therapy tag for elsunersen in SCN2A-DEE seizures

Reuters
·
Jun 22

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated With Scn2a Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

THOMSON REUTERS
·
Jun 22

Praxis Precision Medicines - Elsunersen Well-Tolerated With No Drug-Related Serious Adverse Events

THOMSON REUTERS
·
Jun 22

Praxis Precision Medicines - Elsunersen Shows 77% Sham-Adj Reduction in Monthly Seizures

THOMSON REUTERS
·
Jun 22

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

GlobeNewswire
·
Jun 22

Movement Alert|Praxis Precision Medicines Rises 5.02% in Regular Trading, Trading at $283.05

Market Focus
·
Jun 19

Praxis Precision Medicines' Share Pullback Represents Good Entry Point, RBC Says

MT Newswires Live
·
Jun 18

RBC Initiates Praxis Precision Medicines at Outperform, Speculative Risk With $449 Price Target

MT Newswires Live
·
Jun 18

Movement Alert|Praxis Precision Medicines Rises 5.29% in Regular Trading, Trading at $271.2

Market Focus
·
Jun 17

Praxis Precision Medicines (PRAX) Stock After Vormatrigine POWER1 Miss And POWER2 Pause How Does Valuation Stack Up

Simply Wall St.
·
Jun 15

Praxis Precision Medicines Shareholders Back Directors and Governance

TIPRANKS
·
Jun 13